Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV003135599 | SCV003808703 | uncertain significance | not provided | 2019-08-30 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003973769 | SCV004788156 | uncertain significance | HNRNPA1-related disorder | 2024-02-15 | no assertion criteria provided | clinical testing | The HNRNPA1 c.649G>A variant is predicted to result in the amino acid substitution p.Gly217Ser. This variant was reported in an individual with amyotrophic lateral sclerosis (Table S2, Liu et al. 2021. PubMed ID: 34275688). This variant is reported in 0.0058% of alleles in individuals of Latino descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |